

**February 2020**


# **CYTOTOXICITY ASSAYS**

Prof Asier Unciti-Broceta

THE UNIVERSITY *of* EDINBURGH  
Edinburgh Medical School



# Cell viability reagents



**AlamarBlue**




1 to 4 h





**PrestoBlue**



10 min to 1 h




# Live imaging methods: IncuCyte



# Preliminary toxicology of SRC inhibitor eCF506



PhD thesis of CRAIG FRASER




FRASER, CARRAGHER & UNCITI-BROCETA:  
Patent filed to protect novel family of  
compounds that inhibits SRC family kinases  
with 1000-fold selectivity over ABL kinase

Journal of  
**Medicinal  
Chemistry**


**Rapid Discovery and Structure–Activity Relationships of  
Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell  
Growth via SRC Kinase Inhibition with Exceptional Selectivity over  
ABL Kinase**

Craig Fraser,<sup>†</sup> John C. Dawson,<sup>†</sup> Reece Dowling,<sup>†,‡</sup> Douglas R. Houston,<sup>§</sup> Jason T. Weiss,<sup>†,‡</sup>  
Alison F. Munro,<sup>†</sup> Morwenna Muir,<sup>†</sup> Lea Harrington,<sup>||</sup> Scott P. Webster,<sup>†</sup> Margaret C. Frame,<sup>†</sup>  
Valerie G. Brunton,<sup>†</sup> E. Elizabeth Patton,<sup>‡,||</sup> Neil O. Carragher,<sup>\*,‡</sup> and Aster Unciti-Broceta<sup>\*,‡</sup>

eCF506



Dasatinib



***THANKS FOR YOUR  
ATTENTION***